We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Dermatology

Journal Scan / Research · June 26, 2022

Prognoses of Patients With Melanoma Who Continue/Discontinue Anti–PD-1 Therapy After Achieving a Complete Response

The British Journal of Dermatology

 

Additional Info

The British Journal of Dermatology
Prognoses of patients with melanoma who continue/discontinue anti-programmed death-1 therapy after achieving a complete response in a real-world setting: a multicentre retrospective study
Br J Dermatol 2022 Mar 29;[EPub Ahead of Print], J Kato, K Namikawa, J Uehara, M Nomura, Y Nakamura, H Uhara, H Uchi, S Yoshikawa, Y Kiniwa, Y Nakamura, T Miyagawa, S Matsushita, T Takenouchi, N Hatta, F Ohno, T Maeda, S Fukushima, N Yamazaki

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading